Q4 2025 Inovio Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Inovio Pharmaceuticals Inc (INO) has submitted a Biologics License Application (BLA) for INO-3107 under the FDA's accelerated approval program, with a PDUFA target date set for October 30, 2026.
- The company has extended its cash runway into the fourth quarter of 2026 by rescoping projects and reducing headcount by approximately 15%.
- INO-3107 has shown promising results, with a majority of patients experiencing a 50% to 100% reduction in surgeries, and half of the patients requiring no surgeries in the second year post-treatment.
- Inovio Pharmaceuticals Inc (INO) is advancing its DNA medicine platform, including a Phase II trial for glioblastoma in collaboration with the Dana-Farber Cancer Institute and Akeso.
- The company has made significant progress in its commercial preparations for INO-3107, including market research, targeting segmentation, and selecting key commercial partners.
- The FDA has raised concerns about the eligibility of INO-3107 for the accelerated approval program, noting that the company has not provided adequate information to justify eligibility.
- Inovio Pharmaceuticals Inc (INO) reported a net loss of $84.9 million for the full year of 2025, despite a noncash gain on fair value adjustment related to its warrant liability.
- The company's cash, cash equivalents, and short-term investments decreased from $94.1 million at the end of 2024 to $58.5 million at the end of 2025.
- There is uncertainty regarding the FDA's decision on the accelerated approval, which could impact the company's ability to launch INO-3107 as planned.
- Inovio Pharmaceuticals Inc (INO) is heavily reliant on partnerships to advance its pipeline, which may pose risks if partnerships do not materialize as expected.
Good afternoon, ladies and gentlemen, and welcome to the Inovio fourth-quarter and full year 2025 financial results conference call. (Operator Instructions) This call is being recorded on Thursday, March 12, 2026.
I would now like to turn the call over to Jennie Wilson. Please go ahead.
Good afternoon, and thank you for joining the Inovio fourth-quarter and full year 2025 financial results Conference Call. Joining me on today's call are Dr. Jacqui Shea, President and Chief Executive Officer; Dr. Mike Sumner, Chief Medical Officer; Steve Egge, Chief Commercial Officer; and Peter Kies, Chief Financial Officer.
Today's call will review our corporate and financial information for the quarter and year ended December 31, 2025, as well as provide a general business update. Following prepared remarks, we will conduct a question-and-answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
